Central Nervous System:

INMEDIX CNS research focuses on fundamental mechanisms affecting pain and fatigue in fibromyalgia, as well as how neuro-endocrine function intensifies inflammation in autoimmune diseases like RA and SLE.

For the first time in history, a treatment which affects the probable cause of fibromyalgia is within reach. And, for those with treatment resistant RA, SLE and other autoimmune diseases, understanding how the CNS influences inflammation lead to a meaningful reduction of the burden of pain and joint destruction in patients with crippling rheumatic joint disease. We have expanded the scope of discovery to bridge the gap between immunology and the brain.

See the results of our research on our Fibromyalgia page.


Rheumatology:

Before the creation of the medical subspecialty of rheumatology over 40 years ago, musculoskeletal disorders were poorly characterized as ‘rheumatism’. Such diagnostic ambiguity led to poor therapeutic intervention. Fortunately, exploration of mechanism of action and specific discovery of pathogenic mechanisms of disease finally allowed clinicians to better understand and treat this family of diseases affecting joints and other connective tissues.

The study of rheumatology became the study of the immunology that drives the destructive consequences of rheumatoid arthritis, systemic lupus erythematosis and over one hundred distinct forms of autoimmune joint disease. Rheumatologists became puzzle solvers, and immunology became the language of discovery in the latter half of the twentieth century.

The diagnostic purview of rheumatologists has spread to include regulation of the central nervous system (CNS) which influences sleep physiology, pain perception and autonomic function.

Measurement of autonomic nervous system status using heart rate variability (HRV) has demonstrated predictive power in patients with inflammatory arthritis, including rheumatoid arthritis (RA). For nearly 3 million Americans with RA, immunosuppression has been the sole therapeutic approach to stave off progressive joint destruction. In collaboration with Omegawave, the recent Inmedix HRV study has supported the hypothesis that autonomic cofactors influence inflammatory disease activity (and treatment response). Consequently, a new approach for improving treatment outcome fin RA, and possibly other autoimmune disease, may focus on autonomic tone.

Read more on our Rheumatic Discovery page.